{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:07:17Z","timestamp":1779242837312,"version":"3.51.4"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T00:00:00Z","timestamp":1271980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To determine whether topical levofloxacin 1.5% will successfully treat both levofloxacin\u2010resistant and susceptible <jats:italic>Staphylococcus aureus<\/jats:italic> (SA) and <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (PA) in rabbit keratitis models.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> For levofloxacin\u2010resistant and susceptible SA, respectively, 32 New Zealand White (NZW) rabbits were intrastromally injected with 1000 colony\u2010forming units (CFU). After 4\u2003hr, the corneas of eight rabbits were homogenized to determine onset CFU\/ml. Twenty\u2010four rabbits were divided into three treatments: levofloxacin, vancomycin (cefazolin for levofloxacin\u2010susceptible SA) and saline. Twenty\u2010one drops were administered over 5\u2003hr. One hour post\u2010treatment, the corneas were homogenized for CFU\/ml. For levofloxacin\u2010resistant and susceptible PA, respectively, 32 NZW rabbits were intrastromally injected with 1000\u2003CFU. After 16\u2003hr, the corneas of eight rabbits were homogenized for CFU\/ml. Twenty\u2010four rabbits were divided into three treatments: levofloxacin, tobramycin (ciprofloxacin for levofloxacin\u2010susceptible PA) and saline. Nineteen drops were administered over 8\u2003hr. One hour post\u2010treatment, the corneas were homogenized for CFU\/ml. The CFU\/ml data were analysed for sterilization and non\u2010parametrically for reduction.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Levofloxacin 1.5% significantly reduced more (p\u2003&lt;\u20030.05) levofloxacin\u2010resistant SA than vancomycin; was equivalent to cefazolin (p\u2003&gt;\u20030.05) for levofloxacin\u2010susceptible SA; was equivalent to tobramycin for levofloxacin\u2010resistant PA; was equivalent to ciprofloxacin for levofloxacin\u2010susceptible PA; and significantly reduced more SA and PA than saline and onset. Levofloxacin 1.5% sterilized the corneas in the levofloxacin\u2010resistant and susceptible PA groups (32\/32) and levofloxacin\u2010susceptible SA group (16\/16), but not the levofloxacin\u2010resistant SA group (0\/16).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Levofloxacin 1.5% was effective for reducing SA and PA in the rabbit keratitis models regardless of <jats:italic>in vitro<\/jats:italic> resistance.<\/jats:p>","DOI":"10.1111\/j.1755-3768.2010.01897.x","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T11:18:23Z","timestamp":1272021503000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Topical levofloxacin 1.5% overcomes <i>in vitro<\/i> resistance in rabbit keratitis models"],"prefix":"10.1111","volume":"88","author":[{"given":"Regis P.","family":"Kowalski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric G.","family":"Romanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis S.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M. Q.","family":"Shanks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,27]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"1033","article-title":"Ciprofloxacin versus tobramycin for the treatment of Staphylococcus keratitis","volume":"35","author":"Callegan MC","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_3_1","volume-title":"Methods for Dilution Antimicrobials Susceptibility Tests for Bacteria That Grow Aerobically","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.23.1.60.5417"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.1948-1952.2004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200104000-00013"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00294-0"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.06.025"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-008-0530-1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01334-X"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iio.0000212132.98760.72"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iio.0000212133.75889.6a"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.03.016"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.01.021"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0017"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-3768.2010.01897.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-3768.2010.01897.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:10:42Z","timestamp":1698757842000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-3768.2010.01897.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,27]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1755-3768.2010.01897.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-3768.2010.01897.x","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,27]]},"assertion":[{"value":"2010-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}